ARTICLE | Clinical News
Insugen N: Phase III data
November 5, 2012 8:00 AM UTC
Biocon reported that its biosimilar recombinant insulin products Insugen R and Insugen N each met the primary endpoint of non-inferiority to their respective marketed insulin products in reducing HbA...